ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 25

A Novel Role for Galectin-3 Binding Protein in B Cell Biology and Antibody Secretion

Shinji Okitsu1, Melinda Genest1, Nuruddeen Lewis1, Evgeni Tzvetkov1, Yin Wu2, Andrew Bender1, Arnon Arazi3, Thomas Eisenhaure3, Edward Browne4, Alex Rolfe5, Jonathan Derry6, William Pendergraft III7, Nir Hacohen8, Julie DeMartino5 and Jaromir Vlach5, 1TIP Immunology, EMD Serono Research and Development Institute, Billerica, MA, 2TIP Immunology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3Broad Institute, Cambridge, MA, 4Massachusetts General Hospital, Boston, MA, 5EMD Serono Research and Development Institute, Billerica, MA, 6Iris Bioconsulting, Bainbridge Island, WA, 7Kidney Center, University of North Carolina, Chapel Hill, NC, 8Harvard Medical School, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cell targeting, B cells, Gene Expression, Lupus and basic research

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Antibodies are important in protection against pathogens, but also harbor the potential to cause autoimmune disease when directed against self-antigens. Systemic lupus erythematosus (SLE) is an autoimmune disease where antibodies recognizing nucleic acids and associated proteins form immune complexes that drive inflammation and disease progression. Consequently, targeting B cells and antibody production is a main focus in SLE drug development and we have endeavored to discover new targets in this pathway.

Methods: Here we show results from screening a secreted protein library for effects on Ig secretion by primary human B cells.

Results: We identified galectin-3 binding protein (G3BP) as a soluble factor that enhances antibody production induced by a variety of stimuli in vitro. In an orthogonal translational study we found that the G3BP gene (LGALS3BP) was one of the most upregulated genes across 14 different immune cell types isolated from lupus nephritis (LN) patient blood. LGALS3BP contains an IRF7 binding site in its promoter and we observed increased expression in TLR7-stimulated PBMCs. SLE is characterized by RNAs that induce type I interferon (IFN) inflammation through the innate receptor TLR7. LGALS3BP expression in LN patients correlated with type I interferon-inducible genes indicating that G3BP is part of this pathological process. Indeed, in support of this hypothesis, other investigators have documented upregulated LGALS3BP in active IFN high SLE patients versus healthy controls (Merrill, J.T. et al., ACR abstract 1809, 2013). We found the same LGALS3BP upregulation and correlation with type I IFN in a mouse model of LN. Moreover, upregulation in mouse kidneys correlated with nephritis development. In in vitro studies we found that antibodies against G3BP led to defects in human B cell survival and loss of antibody production.

Conclusion: We hypothesize that targeting G3BP may be a novel approach to inhibit autoantibody production and may benefit patients suffering from antibody-mediated autoimmune diseases, including lupus nephritis.


Disclosure: S. Okitsu, EMD Serono Inc., 3,EMD Serono Inc, 1; M. Genest, EMD Serono Inc, 3; N. Lewis, EMD Serono Inc, 3; E. Tzvetkov, EMD Serono Inc, 3; Y. Wu, EMD Serono, Inc, 3; A. Bender, EMD Serono, Inc, 3; A. Arazi, None; T. Eisenhaure, None; E. Browne, None; A. Rolfe, EMD Serono Inc, 3; J. Derry, Amgen, Merck and Co, 1,EMD Serono, Inc; Curis, Inc; ITeos Therapeutics; Lumos Pharma; Aptevo Therapeutics, 5; W. Pendergraft III, EMD Serono, Inc, 2; N. Hacohen, EMD Serono, Inc, 2; J. DeMartino, EMD Serono Inc, 3,EMD Serono, Novartis, 1,Merck and Co, 1; J. Vlach, Jaromir Vlach, 3.

To cite this abstract in AMA style:

Okitsu S, Genest M, Lewis N, Tzvetkov E, Wu Y, Bender A, Arazi A, Eisenhaure T, Browne E, Rolfe A, Derry J, Pendergraft W III, Hacohen N, DeMartino J, Vlach J. A Novel Role for Galectin-3 Binding Protein in B Cell Biology and Antibody Secretion [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-novel-role-for-galectin-3-binding-protein-in-b-cell-biology-and-antibody-secretion/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-role-for-galectin-3-binding-protein-in-b-cell-biology-and-antibody-secretion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology